Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2003-12-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JAC/DKH029PMID 14657084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Saquinavir

  2012cited by this paper
• The efficacy of lopinavir in individuals experiencing protease inhibitor failure.

  2003cited by this paper
• Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

  2003cited by this paper
• P‐glycoprotein in blood CD4 cells of HIV‐1‐infected patients treated with protease inhibitors

  2003cited by this paper
• Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

  2003cited by this paper
• Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.

  2002cited by this paper
• Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.

  2002cited by this paper
• Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.

  2002cited by this paper
• The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects

  2002cited by this paper
• Low‐dose ritonavir moderately enhances nelfinavir exposure

  2002cited by this paper
• Salvage therapy with amprenavir and ritonavir: Prospective study in 17 heavily pretreated patients

  2002cited by this paper
• Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

  2002cited by this paper
• Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir

  2002cited by this paper
• The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1)

  2002cited by this paper
• P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.

  2002cited by this paper
• Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir

  2002cited by this paper
• Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

  2002cited by this paper
• Long‐term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy

  2002cited by this paper
• The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

  2002cited by this paper
• Pharmacokinetic Enhancement of Protease Inhibitors

  2002cited by this paper
• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  2002cited by this paper
• Low-Dose Ritonavir for Protease Inhibitor Pharmacokinetic Enhancement

  2002cited by this paper
• Antiretroviral Treatment Patterns and Incident HIV‐Associated Morphologic and Lipid Abnormalities in a Population‐Based Cohort

  2002cited by this paper
• ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

  2001cited by this paper
• P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

  2001cited by this paper
• Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

  2001cited by this paper
• Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier

  2001cited by this paper
• Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.

  2001cited by this paper
• [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].

  2001cited by this paper
• Principles and practice of HIV‐protease inhibitor pharmacoenhancement

  2001cited by this paper
• HIV‐Protease Inhibitors Contribute to P‐Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV‐Positive Patients Receiving HAART

  2001cited by this paper
• Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers

  2001cited by this paper
• Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients

  2001cited by this paper
• Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

  2001cited by this paper
• Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.

  2000cited by this paper
• Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.

  2000cited by this paper
• Ritonavir/Saquinavir plus One Nucleoside Reverse Transcriptase Inhibitor (NRTI) versus Indinavir plus Two Nrtis in Protease Inhibitor-Naive HIV-1-Infected Adults (Iris Study)

  2000cited by this paper
• Dual protease inhibitor therapy in the management of the HIV-1

  2000cited by this paper
• Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.

  2000cited by this paper
• P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

  2000cited by this paper
• Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions

  1999cited by this paper
• HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

  1999cited by this paper
• Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.

  1999cited by this paper
• Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

  1996cited by this paper

• Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir

  2025cites this paper
• Elements of Viral Outbreak Preparedness: Lessons, Strategies, and Future Directions

  2025cites this paper
• The oral bioavailability of a pleuromutilin antibiotic candidate is increased after co-administration with the CYP3A4 inhibitor ritonavir and the P-gp inhibitor zosuquidar formulated as amorphous solid dispersions.

  2025cites this paper
• Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS‐CoV‐2

  2025cites this paper
• Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants

  2025cites this paper
• The Effect of Diosmin-Hesperidin Combination on Blood Glucose and Hba1c Levels in HIV-Protease Inhibitor Treated Rattus Norvegicus

  2025cites this paper
• Biotransformation research advances – 2024 year in review

  2025cites this paper
• Solvent-Free One-Pot Synthesis of Butyl N-[(2-Hydroxy-1-naphthyl)(aryl)methyl]carbamate Derivatives and Their Biological Evaluation

  2025cites this paper
• Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters.

  2025cites this paper
• COMPARATIVE EVALUATION OF ARTIFICIAL INTELLIGENCE AND DRUG INTERACTION TOOLS: A PERSPECTIVE WITH THE EXAMPLE OF CLOPIDOGREL

  2024cites this paper
• Enhanced antifungal activity of posaconazole against Candida auris by HIV protease inhibitors, atazanavir and saquinavir

  2024cites this paper
• Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study

  2024cites this paper
• ROS Chronicles in HIV Infection: Genesis of Oxidative Stress, Associated Pathologies, and Therapeutic Strategies

  2024cites this paper
• First-in-Class Small Molecule Degrader of Pregnane X Receptor Enhances Chemotherapy Efficacy.

  2024cites this paper
• Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

  2024cites this paper
• The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies

  2024cites this paper
• Unravelling Insights into the Evolution and Management of SARS-CoV-2

  2024cites this paper
• Biological evaluation of a phosphate ester prodrug of 10-methyl-aplog-1, a simplified analogue of aplysiatoxin, as a possible latency-reversing agent for HIV reactivation.

  2023cites this paper
• Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

  2023cites this paper
• Amidoalkyl Naphthols as Important Bioactive Substances and Building Blocks: A Review on the Current Catalytic Mannich-Type Synthetic Approaches

  2023cites this paper
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?

  2023cites this paper
• Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets

  2023cites this paper
• Metallo-antiviral aspirants: Answer to the upcoming virusoutbreak

  2023cites this paper
• Novel tetrahydronaphthalen-1-yl-phenethyl ureas: synthesis and dual antibacterial-anticancer activities

  2023cites this paper
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• Retinopathy Associated With Ritonavir Treatment for HIV Infection: A Case Series Reappraisal in the COVID-19 Era

  2023cites this paper
• Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review

  2023cites this paper
• COVID‐19 retreats and world recovers: A silver lining in the dark cloud

  2023cites this paper
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• Physiologic Changes During Pregnancy and Impact on Small-Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response

  2023cites this paper
• Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption

  2023cites this paper
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• Outcomes in HIV patients on two different protease inhibitors on second-line antiretroviral therapy: An observational study

  2022cites this paper
• Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels

  2022cites this paper
• Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

  2022cites this paper
• The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

  2022cites this paper
• Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences

  2022cites this paper
• Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study

  2022cites this paper
• Review of Coronavirus disease- 2019 (COVID-19) in Iraq

  2022cites this paper
• An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats

  2022cites this paper
• Dynamic Systematic Benefit Risk Analysis of Antiviral Drug Combination of Lopinavir - Ritonavir for Covid-19 Patient

  2022cites this paper
• Paxlovid-like nirmatrelvir/ritonavir fails to block SARS-CoV-2 transmission in ferrets

  2022cites this paper
• A straightforward synthesis of potentially biologically active novel urea derivatives from 1,2,3,4-tetrahydronaphthalene-2-carboxylic acids

  2022cites this paper
• Reproductive toxicity of ritonavir in male: Insight into mouse sperm capacitation

  2022cites this paper
• The regioselective synthesis of 2,5- and 4,5-disubstituted thiazoles via the cyclization of 2-oxo-2-(amino)ethanedithioates with isocyanides.

  2022cites this paper
• A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies

  2022cites this paper
• nCOVID -19 pandemic outbreak in India - A concise review

  2022cites this paper
• SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors

  2021cites this paper
• Therapeutic potential of HIV-1 entry inhibitor peptidomimetics

  2021cites this paper
• Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat

  2021cites this paper
• COVID-19: inflammatory responses, structure-based drug design and potential therapeutics

  2021cites this paper
• Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (Schizosaccharomyces pombe)

  2021cites this paper
• COVID-19 ARDS: getting ventilation right – Authors' reply

  2021cites this paper
• Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management

  2021cites this paper
• COVID-19 ARDS: getting ventilation right

  2021cites this paper
• Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

  2021cites this paper
• Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins

  2020cites this paper
• Possible therapeutic agents for COVID-19: a comprehensive review

  2020cites this paper
• Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site

  2020influential citation
• Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus

  2020cites this paper
• COVID-19 Treatment: The Race Against Time

  2020cites this paper
• Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients

  2020cites this paper
• Pharmacokinetic Parameters of HIV‐1 Protease Inhibitors

  2020cites this paper
• Carbamate Group as Structural Motif in Drugs: A Review of Carbamate Derivatives used as Therapeutic Agents

  2020cites this paper
• Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2)

  2020cites this paper
• Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy

  2020cites this paper
• Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition

  2020influential citation
• Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective

  2020cites this paper
• Identification of therapeutic target in S2 domain of SARS nCov-2 Spike glycoprotein: Key to design and discover drug candidates for inhibition of viral entry into host cell

  2020cites this paper
• α-Amidoamids as New Replacements of Antibiotics—Research on the Chosen K12, R2–R4 E. coli Strains

  2020cites this paper
• Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

  2020cites this paper
• The Molecular Docking, Synthesis and anti-HIV-1 protease Activity of Novel Chalcones.

  2020cites this paper
• Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis

  2020cites this paper
• A comprehensive review about SARS-CoV-2

  2020cites this paper
• Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding

  2020cites this paper
• Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

  2020cites this paper
• Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19

  2020cites this paper
• A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

  2020cites this paper
• Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

  2020cites this paper
• A review of medications used to control and improve the signs and symptoms of COVID-19 patients

  2020cites this paper
• Desirable drug-drug interactions or when a matter of concern becomes a renewed therapeutic strategy.

  2020cites this paper
• Novel Coronavirus Disease (COVID-19): Causes, Pathogenesis and Efforts of Treatment

  2020cites this paper
• A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors

  2020cites this paper
• Bioinformatic Approaches for Repurposing and Repositioning Antibiotics, Antiprotozoals, and Antivirals

  2019cites this paper
• A Stratified Approach for Cushing’s Syndrome Diagnosis

  2019cites this paper
• Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice.

  2019cites this paper
• Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery

  2019cites this paper
• Computational approaches for improving treatment and prevention of viral infections

  2019cites this paper
• The Pharmacokinetic Interaction between Ivacaftor and Ritonavir

  2019cites this paper
• Iatrogenic Cushing syndrome secondary to enhanced protease inhibitors: Case report and review

  2019cites this paper
• Drug Susceptibility and Replication Capacity of a Rare HIV-1 Subtype C Protease Hinge Region Variant

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment

  2019influential citation
• Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study.

  2019cites this paper
• Synthesis, Spectral Characterization, Docking Studies and Antiviral Activity of Phosphorylated Derivatives of Lopinavir Intermediate

  2019cites this paper
• DEVELOPMENT OF PEDIATRIC ANTI-HIV FORMULATIONS WITH IMPROVED DISSOLUTION CHARACTERISTICS

  2019cites this paper
• Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France

  2019cites this paper
• Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.

  2019cites this paper
• Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation

  2019cites this paper